复星医药：控股子公司FXS887片获临床试验批准

Core Viewpoint - Fosun Pharma has received approval from the National Medical Products Administration for clinical trials of FXS887 tablets for advanced malignant solid tumors [1] Group 1 - Fosun Pharma's subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., is set to conduct Phase I clinical trials of FXS887 in China once conditions are met [1]